its prevalence is between 0.2 and 1.2% [3] . Extra-articular manifestations may arise in AS as a result of uncontrolled inflammation [4] such as anterior uveitis. Other examples include inflammation of the aortic root, which may lead to aortic valve insufficiency and conduction problems in the heart, apical pulmonary fibrosis, inflammatory bowel disease, nonspecific colitis, and psoriasis [4] . The frequency of associated renal abnormalities has been reported to be between 10 and 35%, and includes glomerulonephritis, IgA nephropathy, microscopic or macroscopic hematuria, and amyloidosis [3] . Several more recent studies have shown that urolithiasis is observed among patients with AS [5] [6] [7] . Since urolithiasis may have a relapsing nature and may necessitate surgical intervention [8] , it may cause significant morbidity beyond the morbidity caused by AS alone. Furthermore, urolithiasis can cause chronic kidney disease or urinary tract infections and obstruction. In this review, we will examine the literature related to urolithiasis as an extraarticular sign of AS, and discuss possible biochemical and genetic factors in its pathogenesis. We searched PubMed and Embase for sources using keywords: ankylosing spondylitis together with urolithiasis or nephrolithiasis or renal stone or kidney stone or calcium oxalate or ANKH gene or inflammatory bowel disease or bone or hypopyrophosphaturia in the literature published until 2017. We also checked the references list of relevant studies to identify additional studies. We included studies investigating frequency of urolithiasis in AS, lithogenic and antilithogenic factors responsible for renal stone formation in AS or inflammatory bowel diseases, relationship between ANKH gene and ankylosing spondylitis, and ankylosing spondylitis and bone changes.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by sacroiliac and axial joint inflammations [1, 2] . It is 2-3 times more frequent among men, and
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The evidence for urolithiasis in ankylosing spondylitis
In 1972, Elian et al. reported that 13.6% of AS patients (Table 1) had urolithiasis [9] . They proposed that limited spinal mobility and altered pyelo-pelvic position might be an underlying predisposing factor for urolithiasis. In 1973, Mladevoniç reported that 8.5% of AS patients had kidney stones [10] compared to a frequency of kidney stones of 1.9% among the general population of Croatia. It was also proposed that spinal ankylosis and hip joint involvement were risk factors for stone formation. In 1989, Jimenes Balderas et al. detected urolithiasis in 25% of AS patients. Researchers also reported hyperuricemia in 5 of these 23 patients [11] .
Based on our observation during our routine clinical practice that some of our patients with AS had recurrent urolithiasis, we conducted an ultrasonography (USG)-based study in 2005 [5] and showed the presence of urolithiasis in 20 (24%) of 83 AS patients. In 2006, Incel et al. from Turkey found that 11.3% of AS patients had urolithiasis; however, this rate was not different in comparison with healthy controls. They found that both lumbar and femoral neck bone mineral densities (BMD) were lower among AS patients with urolithiasis and proposed a possible relationship between osteoporosis, urolithiasis, and femoral neck fracture [12] . In 2006, Canales et al. evaluated the frequency of kidney stone among patients with spondyloarthropathy (SpA) including patients with AS and compared the results to that of patients with rheumatoid arthritis (RA). The frequency of self-reported kidney stone was 29.11% among patients with SPA and 12.5% among patients with RA [13] . In their 2011 study with 102 AS patients, Cansu et al. investigated possible predictors of radiographic and functional disability, and they detected urolithiasis in 27.5% of patients with AS [14] . In 2012, Lui et al. found 7.5% of 504 AS patients had urolithiasis, and they reported that patients with renal stones had worse functional indices compared to patients without stone. Additionally, the frequency of peripheral arthritis and requirement for biological drugs were found to be greater among patients with urolithiasis. They also stated that diseases like diabetes and Crohn's disease may have contributed to stone formation in these patients [7] . In 2012, Fallahi et al. found that the frequency of urolithiasis among 163 Iranian patients with AS was 11.7%, in comparison with 5.7% in 7649 normal controls. They found higher values of bath ankylosing spondylitis metrology index (BASMI), bath ankylosing spondylitis functional index (BASFI), and bath ankylosing spondylitis disease activity index (BASDAI) parameters in patients with kidney stone [15] . In their 2014 prospective, in population-based nation-wide study from Sweden, Jakobsen et al. investigated frequency of kidney stone and its predictors in 8572 AS patients that were cohort against 39,639 healthy individuals. The two groups were evaluated for comorbid diseases. At the beginning of the study, frequency of urolithiasis was 1.6% among AS patients and 0.7% in the control group, at the end of the study, these rates were 4 and 1.8%, respectively. They found the unadjusted hazard ratios of urolithiasis for AS compared to population comparators as 2.4 (95% CI 2.1-2.9). In that same study, male sex, inflammatory bowel disease, history of previous urolithiasis, disease severity, and utilization of anti-tumor necrosis factor (TNF) medication were found as predictors for urolithiasis. Even after necessary adjustments for age, inflammatory bowel disease, and history of previous urolithiasis, AS was found to be a risk factor for urolithiasis [8] . Finally, in a 2015 study from Turkey, Resorlu et al. compared 38 AS patients and 38 healthy controls in terms of frequency of kidney stone. They found that urolithiasis was present among 18.4% of AS patients and 10.4% of controls [16] . Most of these studies were conducted in centers that provided tertiary health care services and, therefore, are hampered by both selection and referral bias, and included only small patient numbers. However, the Swedish cohort study included a large database making it less prone to bias and providing more robust statistical evidence. Based on these data, urolithiasis appears to be 2.5 times more frequent among AS patients in comparison with the general population.
Clinical predictors for urolithiasis in AS patients
Previous studies have suggested that hip joint involvement and spinal ankyloses in AS are risk factors for stone formation [9, 10] . Urolithiasis in AS has also been associated with advanced age, longer disease duration, and microscopic haematuria [5] . The Swedish study suggested that a previous history of urolithiasis, presence of inflammatory bowel disease, and treatment with anti-TNF alpha were predictors for urolithiasis. A consistent list of predictors for urolithiasis in AS patients is lacking, due to differences in their designs, limitations in patient numbers, and variations in ethnicities of study populations.
Possible mechanism(s) for the development of urolithiasis
The balance between lithogenic and antilithogenic factors is important for renal stone formation. Urolithiasis may be secondary to multiple underlying factors with a range underlying disease and complex mechanisms involving kidney, intestine, and bone predisposing to disease [17] . Bone remodelling and intestinal changes in the course of AS may change this balance towards stone formation (Fig. 1) . Important antilithogenic factors include the presence of urinary citrate and magnesium, whilst hypercalciuria, hyperoxaluria, hyperuricemia, reduced urinary flow, and dehydration are all lithogenic factors [17, 18] .
The possible role of gastrointestinal system
Recognition of the type of the stone may shed light on its pathogenesis; however, our knowledge about the stone types in AS patients is limited. The most common type of kidney stones observed in the general population is calcium oxalate (CaOx). For the formation of CaOx stones, hypercalciuria and hyperoxaluria are the most common biochemical risk factors [17] . Urolithiasis is also known to be frequent (10.5%) among patients with Crohn's disease [19] , an inflammatory bowel disease. The majority of the stones found in Crohn's disease are also CaOx stones [19] . The pathogenesis of urolithiasis occurring in Crohn's disease involves saponification of calcium with lipids inside the gut lumen and thereby reduced calcium available for binding with oxalate, which is necessary to reduce absorption of oxalate from the bowel. Thus, intestinal oxalate absorption is increased, and this leads to hyperoxaluria and is a risk factor for stone formation in kidneys. It has not been proven that the same mechanism is also responsible for urolithiasis in AS, but it is likely that it may be one of the factors playing role in development of AS-related urolithiasis. A reciprocal clinical and genetic overlaps exist between inflammatory bowel diseases and AS. For instance, subclinical colitis is present in 2/3 of AS patients [20] . Intestinal biopsy examinations show that 26% of AS patients demonstrate a histological appearance similar to what is seen in Crohn's disease, and 10% of the patients are diagnosed with inflammatory bowel disease [21, 22] . Genetic factors common to AS and inflammatory bowel diseases may have a role in this process. For example, HLA-B27 positivity has been reported with the rates of 85 and 33% in AS and inflammatory bowel diseases, respectively [22] . IL23R gene has been shown to be associated with AS and inflammatory bowel diseases [23, 24] . Van Sommeren et al. showed that AS patients have the largest number of risk loci that are shared with inflammatory bowel diseases [25] . Recently calprotectin, which is an indicator of intestinal inflammation, has been shown to be elevated in serum and faeces of patients with AS, and it has been associated with radiological severity and other inflammatory parameters [26, 27] . Calprotectin is especially important for showing macrophage-neutrophil infiltration in inflammatory bowel diseases [28] . Elevated levels of calprotectin in AS suggest possible role of intestinal inflammation in pathogenesis of AS. Also, antibodies against commensal bacteria have been detected in patients with AS [29] , as well as in inflammatory bowel diseases. The most important of these antibodies is antiflagellin, whose titer has been found to be correlated with increased acute-phase response in AS [29] . Flagellin is a molecular component on the bacterial surface, and interacts with TLR5 and induces production of proinflammatory cytokines. Another interesting finding was that Gönüllü et al. found higher blood IgA levels in AS patients with urolithiasis compared to the AS patients who did not have urolithiasis [30] . However, it is not clear whether there is a causal relationship between IgA and urolithiasis in AS patients. Shodjai-Moradi et al. found that the levels of IgA were significantly elevated in patients with active AS compared to patients with inactive AS or RA, or with healthy controls [31] . Other studies have also reported similar results in patients with AS and compared to patients with RA [32, 33] . It has been reported that there is an association between increased AS disease activity and increased serum IgA levels [34] . Ardicoğlu et al. suggested that the increase in IgA levels is a sign of an enterobacterial antigenic stimulation that occurs in the gastrointestinal tract during the active phase of the disease [35] . It is tempting to speculate that enterobacterial antigenic stimulation and subclinical colitis might lead to increase in the levels of IgA and hyperoxaluria. We believe that the possible relationship between IgA, urolithiasis, and enterobacterial stimulation seems to be open for further investigations.
We hypothesize that one of the mechanisms responsible for the development of urolithiasis in AS may be intestinal inflammation occurring during the course of AS, resulting in enteric hyperoxaluria. However, it will be necessary to know whether patients with and without kidney stones differ in terms of presence of intestinal inflammation and hyperoxaluria.
The role of bone turnover
Bone structure is compromised by AS, as the disease causes both new bone formation (ankylosis and syndesmophytes), and leads to osteoporosis and fractures of the trabecular structure of the vertebral column [36] . Factors playing a role in the development of osteoporosis in AS include systemic inflammation, vitamin D deficiency, inappropriate load on bones due to abnormal gait and posture, malabsorption, inflammatory bowel disease, and low body mass index [37] . İncel et al. found an association between femoral neck osteoporosis and urolithiasis. The authors proposed that the development of urolithiasis and osteoporosis might be separate outcomes that stem from a common mechanism [12] . In line with this suggestion, some studies have illuminated that the osteoporotic fractures develop more frequently in patients with urolithiasis than in the general population [38] .
Levels of the bone turnover markers, such as RANK-RANK-L, DKK-1, sclerostin, and osteoprotegerin, are altered during this process [39, 40] . RANK-RANK-L is activated by inflammatory cytokines and it leads to resorption. Osteoprotegerin, on the other hand, has an antiresorptive role. In AS patients, low levels of osteoprotegerin have been detected together with high sRANKL/OPG ratios [41] . It is obviously important to know how the calcium levels change during this bone turnover within the bone structure, which holds 99% of the body calcium. It has been reported that inflammatory cytokines, such as IL-6, IL-1, and TNFalpha, not only play a role in the inflammatory process of AS but are involved in the osteoporosis of AS [42, 43] . It is well known that TNF-alpha and IL-1 are among the most powerful stimulators of bone resorption and are well-recognized inhibitors of bone formation [44] . They may also result in hypercalciuria [45] . Taken together, hypercalciuria may be expected in AS patients due to both immobilization and inflammatory cytokines. There are conflicting studies as to whether or not hypercalciuria is prevalent in patients with AS [44] . In our 2006 study, although urinary calcium levels were increased in AS patients with urolithiasis, the difference was not statistically significant; nonetheless, frequency of hypercalciuria was higher among AS patients with urolithiasis compared to AS patients without urolithiasis [5] . In another study, serum calcium level was found higher among AS patients with urolithiasis [30] . As a conclusion, due to the limited number of urine analysis studies related with lithogenic and antilithogenic factors playing roles in stone formation and also because these studies were crosssectional rather than involving serial analyses, it is unfortunately difficult to reach a definitive conclusion.
Genes and urolithiasis in AS
Environmental and genetic factors play important roles for development of urolithiasis. Those with a family history of urolithiasis have a higher risk [46] . Several recent studies have reported a positive family history and heritability in patients with urolithiasis [47] [48] [49] . This finding indicates the importance of genetic factors. However, there are no studies which have proven a genetic risk factor in patients with AS-related urolithiasis. However, ANKH has been proposed as a genetic marker in AS pathogenesis [50] [51] [52] , as well as a possible contributor to the stone formation [53] . ANKH encoding ANK is a transmembrane transporter protein which serves to transport intracellular pyrophosphate out of the cell, and thus maintains a balance in inorganic pyrophosphate (PYP) levels [54] . Mutations in ANKH result in chondrocalcinosis and craniometaphyseal dysplasias. In addition, functional loss that develops as a result of the mutations in ANKH leads to the arthritic process, new bone formations, and ankylosis that are characteristics of AS [54] . Normally, inorganic pyrophosphate inhibits calcification [55] , and pyrophosphate presents in urine and prevents formation of apatite crystals [56] . Hypopyrophosphaturia is, therefore, a risk factor for urolithiasis [57] . Considering a possible role of ANKH in the development of urolithiasis, we analyzed 6 single nucleotide polymorphisms within ANKH in 23 patients with AS [53] , but did not find any association between ANKH polymorphism and renal stones.
ANKH has also significance in terms of AS. Tsui et al. reported 5-Flanking region of ANKH to be a novel genetic marker for AS [50] . The same researchers showed that while two intronic markers at the 3′ end of ANKH gene were associated with AS in males, two intronic markers at 5′ end of this gene were associated with AS in females [51] . Liu et al. also showed that variation in ANKH influences susceptibility to AS in Chinese patients [52] . However, no significant relationship between gender and ANKH gene was identified in this study. On the other hand, Pimentel Santos et al. and Timms et al. stated that ANKH was not associated with AS and had no effect on the severity of the disease [58, 59] . Differences in these study results may have arisen from different ethnicities of the study populations, variations in case definitions, and differences in analytical methods for the detection of ANKH marker variants. In summary, ANKH gene polymorphism deserves further research, which may yield interesting results with regard to its possible roles in AS pathogenesis and stone formation.
As treatment drugs and urolithiasis
Drug-induced urolithiasis has a prevalence of 0.44% (0.59% in women and 0.37% in men) [60] . Sulfasalazine is one of the drugs that induce stone formation. Acetylsulfapyridine is a metabolite of sulfasalazine (SSZ), which is usually used for peripheral arthritis seen in the course of SpA including AS. SSZ is also used in patients with RA, inflammatory bowel diseases, and juvenile chronic arthritis. In the literature, the development of urolithiasis due to SSZ use has been reported in patients with psoriatic arthritis [61] , juvenile chronic arthritis [62] , and ulcerative colitis [63] . Although the renal stone formation stemming from acetylsulfapyridine was confirmed by reflectance infrared spectroscopy and gas chromatography-mass spectrometry in some case reports [64] , it is not clear whether urolithiasis results from SSZ or disease itself. It has been reported that there was no concrete association between SSZ use and renal stone formation in AS patients [5] . Further studies are needed to elucidate the potential role of SSZ on urolithiasis. Other medications that are used in the treatment of AS are nonsteroidal anti-inflammatory drugs (NSAIDs) and anti-TNF-alpha agents. There are no conclusive data implicating anti-TNF-alpha agents and NSAIDs as contributors to renal stone formation in AS. However, it has been reported that NSAIDs may lead to papillary necrosis and sometimes mimics staghorn calculi [65] .
Clinical importance of urolithiasis
As a chronic disease, AS impairs life quality, increases morbidity and mortality, and increases health costs [66] . Patients with AS-associated urolithiasis have higher recurrence rates in comparison with cases of urolithiasis among the general population [8] . In one of our studies, among 23 patients with urolithiasis, 10 patients experienced only single attack of urolithiasis, whereas 13 patients had history of multiple attacks [53] . Another interesting feature of AS-associated urolithiasis is that requirement for surgical intervention is three times more frequent in comparison with urolithiasis seen in the general population [53] . This is somewhat related to the more complicated course seen in AS-associated urolithiasis. In the study by Jakopsen et al., extracorporeal shock wave lithotripsy (ESWL) was performed in 64% of patients, ureteroscopic procedures was performed in 25%, surgical intervention was performed in 2%, percutaneous nephrolithotomy was performed in 6%, and retrograde intrarenal surgery was performed in 3% of their patients. Predictors of surgical requirement include previous urolithiasis, advanced age, and atherosclerotic heart disease. Requirement of surgical intervention in the presence of atherosclerotic disease further increases the complexity of these cases.
Another downside of AS-related urolithiasis is that it can cause pyelonephritis. Unfortunately, there is no data from AS patients on this subject. However, 4-23% of patients with Crohn's-associated urolithiasis develop pyelonephritis [67, 68] . This rate is 10-100 times higher compared to the general population [69] . Some patients with AS receive anti-TNF treatment, and this makes them more susceptible to such complications. Recurrent renal stone formations and repeated pyelonephritis attacks may lead to chronic kidney disease (CKD) [70] . Vupputuri et al. reported that the likelihood of CKD was twofold higher among persons with history of urolithiasis [71] . Another potential risk factor for CKD in case of urolithiasis is percutaneous nephrolithotomy. Following this procedure, 16 .4% of patients may develop disturbance of renal functions [72] . Therefore, both the adverse effects of the stones on kidneys and interventions aimed to treat them pose threat to the renal functions.
Future implications and conclusions
Urolithiasis is an extra-articular manifestation of AS. There is limited data concerning the frequency of urolithiasis, which may be because of the little awareness on this subject. Increasing awareness would trigger future studies on this topic, which would help us better understand the ethnic and environmental factors that play role in development of urolithiasis. According to the limited data available, urolithiasis has the potential of increasing morbidity and mortality of the disease. For this reason, studies related to the mechanisms involved in development of stones are necessary. Stone formation may be attributed to multiple mechanisms. Combined effects of bone resorption caused by inflammatory cytokines and immobilization, and possible hypercalciuria, increased oxalate absorption and hyperoxaluria resulting from intestinal inflammation, and genetic factors related with stone formation may create tendency towards urolithiasis. Research aimed at these mechanisms would enlighten this topic and offer necessary measures for prevention. Further studies including repeated 24 h urinary sampling analysing lithogenic and antilithogenic factors in urine in AS patients with and without a history of urolithiasis, as well as analysis of stone composition in AS patients, are expected to give further indications to the pathogenesis involved in stone formation in AS patients.
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